Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Regulatory Post Marketing Surveillance of Intelence Tablet

Trial Profile

Regulatory Post Marketing Surveillance of Intelence Tablet

Phase of Trial: Phase IV

Latest Information Update: 25 Apr 2015

At a glance

  • Drugs Etravirine (Primary)
  • Indications Acquired immunodeficiency syndrome
  • Focus Adverse reactions
  • Sponsors Janssen
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 29 Sep 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
    • 11 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top